Privia Health raises 2026 guidance after its Medicare savings climb 60% to $374 million
Privia Health has increased its 2026 adjusted EBITDA guidance to $174 million-$177 million, up from previous estimates, following a significant rise in Medicare shared savings. Its ten accountable care organizations achieved $374.0 million in shared savings for 2025, a nearly 60% increase from the prior year. This amount is distributed among Medicare, ACOs, and providers and does not represent Privia's direct revenue or profit.
Privia Health Group raises FY26 sales guidance to $2.55B-$2.60B
Privia Health Group Inc. has increased its fiscal year 2026 sales guidance to $2.550 billion-$2.600 billion, surpassing its previous outlook and analyst estimates. This upward revision by $50 million on both the lower and upper bounds demonstrates strong confidence in the company's future revenue trajectory. The revised guidance, with a new midpoint of $2.575 billion, also comfortably beats the market consensus of $2.457 billion.
Form 8K Privia Health Group Inc For: 18 November By Investing.com
This article reports that Privia Health Group Inc. filed a Form 8K on November 18, 2026. The article itself is brief, primarily serving as a notification of the filing and a gateway to Investing.com's financial markets platform. It includes a reference to Privia Health Group Inc.'s stock symbol, PRVA.
Ten care groups at Privia Health (PRVA) generated 59.7% more in Medicare shared savings.
Privia Health Group, Inc. (PRVA) reported $374.0 million in Medicare Shared Savings Program (MSSP) shared savings for 2025, a 59.7% increase from the previous year. The company's ten Accountable Care Organizations (ACOs) managed over $4.0 billion in healthcare benchmark spend for more than 297,000 Medicare beneficiaries, leading to significant cost reductions and improved patient outcomes. Based on these strong results, Privia Health increased its full-year 2026 financial guidance for Adjusted EBITDA, GAAP revenue, Care Margin, and Platform Contribution.
PRVA Q3 2026 deep dive: acquisitions and provider growth drive expansion, profitability lags expectations
Privia Health Group (NASDAQ:PRVA) reported strong Q3 2026 revenue, beating Wall Street expectations with a 13.2% year-on-year increase, driven by new provider signings and expansion in value-based care. However, the company's non-GAAP profit per share fell below analyst estimates, despite management raising its full-year outlook. Future growth is expected through organic provider expansion, strategic acquisitions like American Choice Healthcare, and continued focus on diversified value-based care models.
Privia Health Group, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:PRVA)
Privia Health Group, Inc. (PRVA) announced its Q3 2026 earnings, reporting an EPS of $0.21, which missed estimates by $0.02. However, the company's revenue of $656.96 million surpassed expectations by $46.34 million, representing a 13.19% year-over-year increase. The company published a slide deck in conjunction with their earnings call.
PRVA Q3 2026 deep dive: acquisitions and provider growth drive expansion, profitability lags expectations
Privia Health Group (NASDAQ:PRVA) reported Q3 2026 results with revenue beating Wall Street expectations, driven by strong new provider signings and expansion in value-based care. However, non-GAAP profit per share lagged estimates due to scaling and mix effects. The company's outlook emphasizes continued expansion through organic growth and strategic acquisitions, while aiming to sustain EBITDA margin expansion.
Privia Health Raises 2026 Outlook as Adjusted EBITDA Grows 21.9%
Privia Health (Nasdaq: PRVA) has raised its full-year 2026 outlook following a 21.9% increase in nine-month adjusted EBITDA, driven by significant growth in providers, attributed lives, and practice collections. The company also announced a $36 million acquisition of American Choice Healthcare MSSP to expand its value-based care footprint in 2027, while planning to exit a Montana partnership. With a strong, debt-free balance sheet, Privia projects robust free cash flow conversion but cautions that guidance is subject to market uncertainties and regulatory risks.
PRVA: Privia Health Group Inc Latest Stock Price, Analysis, News and Trading Ideas
Privia Health Group Inc. (PRVA) closed at $24.04, up 1.35% today. The company reported strong Q3 '26 earnings with GAAP EPS up 10.53% YoY and revenue up 13.19% YoY, leading to raised full-year 2026 guidance. Analysts anticipate a 29.22% upside for the stock.
Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results
Privia Health (Nasdaq: PRVA) reported strong third-quarter 2026 results with revenue up 13.2% to $657.0 million and net income attributable to Privia increasing 96.6% to $13.5 million. The company raised its full-year 2026 financial outlook, expecting revenue between $2,500–$2,550 million and adjusted EBITDA of $154–$157 million. Privia also announced the acquisition of American Choice Healthcare MSSP, which will add over 36,000 attributed lives, and its exit from the Montana partnership.
Privia Health Raises 2026 Revenue Guidance to $2.55B
Privia Health reported a strong third-quarter 2026 with revenue increasing 13.2% to $657 million and net income soaring 96.6% to $13.5 million. Following this performance, the company raised its 2026 revenue guidance to a range of $2.50 billion–$2.55 billion and adjusted EBITDA guidance to $154 million–$157 million. Privia also announced the acquisition of American Choice Healthcare MSSP for $36 million, expected to serve over 36,000 attributed lives.
Privia Health Group, Inc. (PRVA) Tops Q3 EPS by 12c ; Offers Guidance
Privia Health Group, Inc. (PRVA) reported strong third-quarter results, surpassing analyst estimates with an EPS of $0.21, significantly higher than the projected $0.09. The company also exceeded revenue expectations, bringing in $656.96 million against a consensus of $610.75 million. Furthermore, Privia Health Group provided optimistic FY2026 revenue guidance, forecasting $2.5-2.55 billion, which is above the current consensus of $2.46 billion.
Privia Health Group earnings beat by $0.12, revenue topped estimates
Privia Health Group (NASDAQ: PRVA) reported strong third-quarter results, with EPS of $0.21, significantly surpassing analyst estimates of $0.09. The company also exceeded revenue expectations, bringing in $656.96M against a consensus of $610.75M. Furthermore, Privia Health Group provided optimistic FY 2026 revenue guidance, projecting $2.50B-$2.55B, higher than the analyst consensus of $2.46B.
Privia Health Raises 2026 Revenue Guidance to $2.55B
Privia Health (NASDAQ:PRVA) reported a strong third quarter in 2026, with revenue climbing 13.2% to $657 million and net income soaring 96.6% to $13.5 million. The company has raised its full-year 2026 revenue guidance to $2.50 billion–$2.55 billion and adjusted EBITDA guidance to $154 million–$157 million, following a $36 million acquisition of American Choice Healthcare MSSP. Privia also announced an exit from its Montana partnership, expecting no material impact on 2027 adjusted EBITDA.
Privia Health (NASDAQ:PRVA) posts better-than-expected sales in Q3 2026, guides for strong full-year sales
Privia Health (NASDAQ:PRVA) reported better-than-expected Q3 2026 revenue of $657 million, an increase of 13.2% year-on-year, and provided strong full-year revenue guidance of $2.53 billion. While revenue and EBITDA exceeded analyst consensus, adjusted EPS of $0.21 missed estimates. Despite the EPS miss, the company's long-term revenue growth and improving operating margins suggest healthy underlying demand.
Privia Health (PRVA) Q3 Earnings and Revenues Top Estimates
Privia Health (PRVA) reported strong third-quarter results, with earnings of $0.1 per share exceeding the Zacks Consensus Estimate of $0.09 and revenues of $656.96 million surpassing estimates by 9.57%. The company has consistently beaten revenue expectations in the last four quarters. Despite this performance, Privia Health's shares have underperformed the S&P 500 year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
Privia Health (PRVA) reports Q3: everything you need to know ahead of earnings
Privia Health Group (NASDAQ: PRVA) is set to report its Q3 earnings before market hours on Thursday. The company previously beat revenue expectations last quarter but missed EPS estimates. Analysts generally maintain their estimates for this quarter, anticipating 5.3% year-on-year revenue growth.
Privia Health Expands VBC Footprint with Acquisition of American Choice Healthcare MSSP Business
Privia Health Group, Inc. (Nasdaq: PRVA) has acquired American Choice Healthcare MSSP, LLC (ACH) for approximately $36 million, expanding its value-based care footprint. This acquisition adds over 36,000 attributed lives to Privia's Medicare Shared Savings Program starting in 2027 and is expected to positively impact Attributed Lives and Adjusted EBITDA in the same year. The transaction scales Privia Care Partners and offers synergy opportunities for providers to join Privia's Medical Groups.
Privia Health Group, Inc. (PRVA) Stock forecasts
Argus raised its target price for Privia Health Group Inc. (PRVA) to $24.00 on October 21, 2026. Privia Health Group Inc. is described as a technology-driven, national physician-enablement company with a current price of $21.48. The report provides a summary and suggests upgrading for full access to premium tools and detailed insights.
Vanguard reports a passive stake in Privia Health (PRVA) and sole voting power over 970,727 shares.
Vanguard Capital Management reported a 5.09% passive stake in Privia Health Group, Inc. (PRVA) as of September 30, 2026, holding 6,513,393 shares of common stock. The filing indicates Vanguard possesses sole voting power over 970,727 shares and sole dispositive power over all 6,513,393 beneficially owned shares, with no shared voting or dispositive power. This Schedule 13G filing combines holdings from Vanguard funds and client securities where Vanguard affiliates exercise authority.
Privia Health Group, Inc. Estimates – NASDAQ:PRVA
This article provides an overview of Privia Health Group, Inc. (NASDAQ: PRVA) financial data and analyst estimates available on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform also visualizes trends over time for the company.
Privia Health renews Anthem deal. Target for Privia Health stock is USD 31.00
Privia Health Group (PRVA) has renewed its Anthem agreement in Virginia, preserving in-network access for its physicians. The company reported strong Q2 2026 results with revenue up 21.40% to USD 632.63 million and adjusted EBITDA up 29.00%. Analysts maintain a consensus target of USD 31.00 for Privia Health stock, with the valuation linked to continued operational execution.
Privia Health renews Anthem deal. Target for Privia Health stock is USD 31.00
Privia Health (PRVA) has renewed its agreement with Anthem in Virginia, ensuring continued in-network access for its physicians. The company reported strong second-quarter revenue of USD 632.63 million, a 21.40% year-over-year increase, and analysts maintain a consensus target of USD 31.00 for the stock. Privia Health is set to release its third-quarter 2026 results on November 5, 2026.
Privia Health sets November 5 results date: what it means for Privia Health stock
Privia Health (PRVA) is set to release its third-quarter and nine-month results on November 5, 2026, which will serve as a crucial test for its raised 2026 outlook. The company reported strong second-quarter performance with practice collections reaching USD 970.00 million and adjusted EBITDA rising 29.00 percent year over year. Privia Health maintains financial flexibility with over USD 412.00 million in cash and no debt, and continues to scale its operating model by expanding its provider network.
Privia Health sets November 5 results date: what it means for Privia Health stock
Privia Health (PRVA) has announced November 5, 2026, as the date for its third-quarter and nine-month financial results, a crucial event following strong second-quarter performance where revenue rose 21.40% to $632.63 million and adjusted EBITDA increased by 29.00%. The company, which is expanding its provider network and maintaining financial flexibility with over $412 million in cash and no debt, is expected to provide an update on its raised 2026 outlook. As of October 13, 2026, Privia Health stock was trading at $21.65, with a market capitalization of $2.7 billion.
Privia Health Group, Inc. (PRVA) Stock Forecasts
The article provides a stock forecast for Privia Health Group Inc. (PRVA), a technology-driven, national physician-enablement company. It references an Argus report from October 7, 2026, which offers an earnings estimate and a current price of $20.85. The full report is available for premium subscribers.
Privia Health Group, Inc. (PRVA) Stock forecasts
Argus has issued a quantitative report on Privia Health Group, Inc. (PRVA), a technology-driven physician-enablement company. The report includes an earnings estimate and a current price of $20.85, with a price target. Full details are available in the downloadable report.
Privia Health Group, Inc. (PRVA) Stock forecasts
Argus recently published a report on Privia Health Group Inc. (PRVA), a technology-driven, national physician-enablement company. The report includes a rating and an earnings estimate, with the current price at $20.91 and a price target available in the full report. Users can upgrade to premium tools for exclusive reports and detailed company profiles.
At 8 a.m. Nov. 5, managers will discuss Privia Health's results.
Privia Health Group (Nasdaq: PRVA) is set to release its third-quarter 2026 financial results before market open on November 5, 2026, with the press release expected by 7:00 am ET. Following the release, management will host a conference call at 8:00 am ET to discuss the results and future financial and operational outlook. A live webcast and replay will be available for those interested in listening.
No voting power accompanies Abigail P. Johnson's reported stake in Privia Health (PRVA).
FMR LLC and Abigail P. Johnson reported beneficial ownership of 5.0% of Privia Health Group, Inc. (PRVA) common stock as of September 30, 2026, totaling approximately 6,385,121 shares. While FMR LLC holds sole voting power over a significant portion of these shares, Abigail P. Johnson reported no voting power, but both hold sole dispositive power over their reported shares. The filing indicates that no other single person's interest exceeded 5% of the outstanding common stock.
Privia Health stock weighs 21.4 percent Q2 growth against slower guidance
Privia Health Group's stock (PRVA) closed at USD 20.28 on October 6, 2026, with analysts setting a USD 31.00 consensus target despite the company's Q2 growth of 21.4% and a potential second-half slowdown. The company reported substantial Q2 practice collections of USD 970 million, a 12.4% increase year-over-year, and a 29% rise in adjusted EBITDA to USD 37.4 million, but guidance suggests a deceleration in growth for the latter half of 2026. Despite this, the stock remains near its yearly low, with analysts maintaining a "Moderate Buy" consensus.
Privia Health Group, Inc. (PRVA) Stock forecasts
Argus has raised its target price for Privia Health Group, Inc. (PRVA) to $19.00. The company is described as a technology-driven, national physician-enablement company. The current price of PRVA stock is $20.45.
Full Transcript: Privia Health Gr Q2 2026 Earnings Call
Privia Health Group (NASDAQ: PRVA) reported strong Q2 2026 financial results, including 12.4% practice collection growth and a 29% increase in adjusted EBITDA, leading to a raised 2026 outlook. The company expanded into New Jersey, now operating in 25 states, and emphasized its robust balance sheet, AI deployment for efficiency, and consistent provider retention. Privia continues to focus on growing its community-based medical groups and value-based care programs, managing an estimated $15.7 billion in total medical spend.
Privia Health Group, Inc. (PRVA) stock price, news, quote and history
This article provides a detailed overview of Privia Health Group, Inc. (PRVA), including its current stock price, financial statistics, and recent performance. It covers key financial metrics like market cap, P/E ratio, and EPS, alongside a company overview describing its operations as a physician-enablement company. The content also features analyst insights, earnings trends, and performance comparisons against the S&P 500 benchmark.
Privia Health stock reports strong Q2 growth and guidance
Privia Health (PRVA) reported strong Q2 2026 results, with revenue up 21.40% year over year to USD 632.63 million, significantly beating analyst expectations. The company also provided fiscal 2026 guidance targeting the high end of USD 2.35 billion to USD 2.45 billion. Analysts largely rate the stock as a "buy," with a consensus 12-month price target of USD 31.00.
Privia Health Group, Inc. (PRVA) Stock forecasts
Argus has lowered its target price for Privia Health Group, Inc. (PRVA) to $18.00. The current stock price for PRVA is $19.71. Privia Health Group Inc. is described as a technology-driven, national physician-enablement company.
Privia Health Group stock hits 52-week low at 19.52 USD
Privia Health Group Inc.'s stock has fallen to a 52-week low of $19.52, reflecting a 14.45% decline over the past year and a -16.28% year-to-date return amidst challenges in the healthcare sector. Despite this, InvestingPro analysis suggests the stock is undervalued and in oversold territory, with analysts maintaining a bullish outlook and price targets between $24 and $40. The downturn comes even after the company reported strong Q2 2026 financial results, surpassing Wall Street expectations for both earnings and revenue.
Privia Health Group (PRVA) Stock Looks Rich Against Current Earnings
Privia Health Group (PRVA) stock closed at US$19.85, but its P/E ratio of 90.2x is significantly higher than the healthcare sector average of 24.0x, suggesting it is overvalued based on current earnings. Despite a 23.1% fall in share price over the past five years, the market is paying a rich premium for its current profits. Simply Wall St's analysis indicates that the stock is overvalued when compared to a tailored benchmark considering its growth profile, margins, size, and risk.
Privia Health Group Inc. (PRVA) Shareholding Pattern – Promoters, FIIs & DIIs
This article provides a detailed shareholding pattern for Privia Health Group Inc. (PRVA), listing institutional investors with holdings over 1% and their changes in shares. It also includes recent insider trading activities, specifically sell transactions by David Mountcastle and Parth Mehrotra in March 2026. Financial metrics for PRVA, such as market cap, revenue, P/E ratio, and dividend yield, are also presented as of September 16, 2026.
Responsive Playbooks and the PRVA Inflection
Privia Health Group Inc. (NASDAQ: PRVA) is showing weak near and mid-term sentiment but a neutral long-term outlook, with its support levels currently being tested. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles and offering specific entry, target, and stop-loss zones. Despite the weak sentiment, an exceptional 41.8:1 risk-reward setup is identified, targeting a 12.4% gain against a 0.3% risk.
New investor group tops 5% stake in Privia Health (NASDAQ: PRVA)
An investment group including Puma Growth Holdings and Rubicon Founders has disclosed a 5.07% beneficial ownership stake in Privia Health Group, Inc. (PRVA), acquired for approximately $138.4 million. The group intends to review its investment continuously and may engage with company management and other stakeholders, signaling an active-investor approach. This disclosure was made via a Schedule 13D filing, indicating potential intent to influence company control.
Adam Boehler Discloses Investment in Privia Health Group with 5.07% Stake
Adam Boehler, through Rubicon Founders, has acquired a 5.07% stake in Privia Health Group, Inc. common stock, as disclosed in a Schedule 13D filing on September 8, 2026. Boehler intends to engage with Privia Health's leadership and other stakeholders to review his investment, with the possibility of buying or selling shares based on ongoing evaluations. Boehler is a prominent American investor known for founding Rubicon Founders, a healthcare-focused investment firm.
Healthcare Technology for Providers Stocks Q2 Teardown: Privia Health (NASDAQ:PRVA) Vs The Rest
This article provides a Q2 earnings teardown for healthcare technology providers, focusing on Privia Health (NASDAQ:PRVA) and its peers. It highlights the strong Q2 performance of the sector, with revenues beating estimates, and details the individual results of Privia Health, Evolent Health (NYSE:EVH), Astrana Health (NASDAQ:ASTH), and Omnicell (NASDAQ:OMCL), noting their revenue growth, analyst estimate beats, and stock performance. The article also touches on market risks and the impact of AI and geopolitics.
(PRVA) Volatility Zones as Tactical Triggers
This article analyzes Privia Health Group Inc. (NASDAQ: PRVA), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies key support and resistance levels, presenting an exceptional risk-reward setup. The piece also outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
Enterprise value to revenue forward of Privia Health Group, Inc. – NASDAQ:PRVA
The article focuses on the enterprise value to revenue forward metric for Privia Health Group, Inc. (NASDAQ: PRVA). It appears to be a financial data point presented by TradingView, indicating a specific valuation multiple for the company. The content primarily lists navigation and administrative information, with the core financial data point being "Enterprise value to revenue forward."
Price to sales forward of Privia Health Group, Inc. – NASDAQ:PRVA
The article displays the "Price to sales forward" metric for Privia Health Group, Inc. (NASDAQ: PRVA) on a TradingView page. It shows a table with "Period," "Value," "Change," and "Change %" but the specific financial data is not populated. The content primarily consists of navigation links and general information about TradingView.
Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?
Privia Health Group (PRVA) recently reported strong Q2 2026 results, raising its full-year revenue outlook and appointing an experienced healthcare executive, Dr. Opella Ernest, to its Board. This positive guidance and new expertise could significantly influence the company's long-term investment narrative, especially in scaling its value-based care model. Investors should consider these developments while also weighing potential risks like rising healthcare labor and technology costs.
Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?
Privia Health Group (PRVA) recently reported strong Q2 2026 results with increased sales and profitability, raising its full-year 2026 GAAP revenue outlook to the high end of its prior range. The company also appointed Dr. Opella Ernest to its Board, bringing valuable healthcare expertise. Investors should consider how this stronger guidance and new board addition impact Privia's investment narrative, particularly concerning its ability to manage rising costs and scale its value-based care model.
Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
Privia Health Group, Inc. has announced the appointment of Dr. Opella Ernest to its Board of Directors, effective September 1, 2026. Dr. Ernest, who also joins the Compliance Committee, brings over 20 years of healthcare executive experience, including significant expertise in value-based care and clinical operations. This appointment is expected to bolster Privia Health's growth and network expansion across the U.S.
Privia Health adds Dr. Opella Ernest to board of directors
Privia Health Group Inc. (NASDAQ:PRVA) has announced the appointment of Dr. Opella Ernest to its board of directors, effective September 1, 2026. Dr. Ernest, who currently serves as President of HCSC Markets at Health Care Service Corporation, will also join the board’s Compliance Committee. Her extensive background in healthcare leadership and clinical practice is expected to bolster Privia Health's strategic direction.